PDB124 Direct costs of diabetic supplies in the U.S: An analysis using 2010 medical expenditure panel survey (MEPS) data  by Heinrich, K.H. & Chandran, A.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A259
respectively, which shows that usage of drugs associated with higher SHE risks var-
ies between countries. E.g. in type 1 DM 42.65% patients in Hungary use basal-bolus 
with human basal (related to 1.1 events/person-year), while only 8% in Croatia. In 
type 2 DM 9.37% patients in Hungary use basal-bolus regimen with basal human 
insulin (0.6 events /person-year), and only 0.5% in Croatia. ConClusions: Rates 
of SHEs differ for T1, T2 and drug regimens. Various treatment schemes prevail in 
analysed countries, which result in different total (estimated) risks. However, other 
factors may impact the actual SHE incidence and motivate treatment selection in 
the first place. Therefore the results should not be used to draw conclusions regard-
ing the overall quality of DM patients care.
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objeCtives: The Syreon model was developed to predict the long term effects 
of screening, treatment and control of type 2 diabetes. After a successful internal 
and external validation the model is capable of analyzing the consequences of 
different macro-level policy interventions. The aim of this analysis was to assess 
the cost-effectiveness of the introduction of a risk stratified population screening 
compared to no screening in Hungary. Methods: The screening program consists 
of two major elements. The first covers the use of the internationally validated 
FINDRISC questionnaire to identify people at high risk of diabetes. Answers to the 
questionnaire are simulated based on individual characteristics. The second part of 
the module refers the high risk (FINDRISC score > = 12) population to oral glucose 
tolerance test. After completion of the screening program, patients enter the disease 
progression and treatment module. The screening process can be repeated over 
defined periods, e.g. every 3 years. Results: Introduction of 3 yearly risk stratified 
screening for 50-60 age groups with not known diabetes was estimated to result 
in an incremental cost-effectiveness ratio of 32 000 PPP $/QALY. The results were 
sensitive to the starting age of the target group, the frequency and the stopping age 
of the organized screening. ConClusions: Risk stratified screening program was 
predicted to be cost-effective compared with no screening in Hungary in certain 
age-groups. Early diagnosis of type 2 diabetes contributes to earlier treatment that 
results in better health and less complications.
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objeCtives: The total estimated cost of diagnosed diabetes in the United States 
(US) in 2012 was $245 billion. Although the cost of diabetic supplies is reported to 
be less than 2% of total expenditures, the fractional cost contribution of the most 
common insulin delivery devices, critical to disease management, remain unknown. 
The objective of this study is to understand the cost distribution among pharmacy 
benefit diabetic supplies and quantify the impact of manual insulin delivery devices 
on the overall cost of diabetes in the US. Methods: A cross-sectional analysis 
of the 2010 Medical Expenditure Panel Survey (MEPS) database was conducted. 
Diabetic supplies were identified from the linked prescription file and categorized 
through identification of National Drug Codes, prescription names and prescription 
form variables. Non-pharmacy benefits including insulin pumps were excluded. 
Expenditures were calculated as the sum source payments and reported in 2012 
dollars. Weighted mean expenditures per diabetic were calculated using SAS 9.2 
SURVEYMEANS procedure. A prevalence-based approach was used to extrapolate 
to the 2012 U.S. diabetic population. Results: 2,440 diabetics were included. The 
sample was 55% female and 12% uninsured with a mean age of 58 (±16.48). The 
estimated total diabetic supply expenditures in the U.S. in 2012 were $3,598,491,566. 
Test strips were the largest contributors to this category (74.7%, $2,689,696,646) fol-
lowed by insulin pens (7.1%), pen needles (6.8%) and syringes (5.1%). Insulin delivery 
devices (limited to insulin pen needles and insulin syringes) contribute 0.24% of 
U.S. direct medical expenditures and 0.17% of the total U.S. expenditures on diabe-
tes. ConClusions: These results highlight the fractional contribution that diabetic 
supplies, and more specifically manual insulin delivery devices, contribute to the 
overall costs attributed to diabetes in the U.S. Further research should consider 
the positive cost implications that such devices may have on diabetes outcomes.
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objeCtives: Our objectives were to understand patient experience with and uti-
lization of manufacturer-sponsored patient support programs for type 2 diabetes 
(T2DM) injectable therapy. Methods: Data for these analyses were drawn from 
a larger cross-sectional survey evaluating treatment adherence and persistence 
among T2DM patients in the US age ≥ 18 who had been prescribed an injectable 
medication. Patients were recruited from a general-population on-line panel, and 
recruitment was stratified by medication and discontinuation status. Analyses are 
limited to the 3 medications for which ≥ 25 respondents reported using the cor-
responding patient support program: exenatide once weekly, liraglutide, insulin 
glargine. Proportions were calculated using a drop-out weighting method. Results: 
Bydureon Steady Support (BSS) was utilized by 26% of exenatide once weekly 
patients (51/200), 14% of liraglutide patients (83/598) utilized Victoza Care (VC), 
and 10% of insulin glargine patients 48/488) utilized Lantus Connection (LC). Those 
inadequately controlled by metformin (MET) monotherapy. This study aimed to 
understand the treatment regimens of Medicare Advantage with Prescription Drug 
coverage (MAPD) patients in a large national health plan who newly initiate MET 
monotherapy, and assess factors associated with changes in therapy in the 12 
months after MET initiation. Methods: This was a retrospective cohort analysis 
of medical and pharmacy claims of 17,527 MAPD members aged 18-89, with ≥ 1 
medical claim containing a primary diagnosis or ≥ 2 medical claims containing a 
secondary diagnosis of T2DM, and with an initial prescription fill for MET between 
1/1/2008 and 9/30/2011. Demographic and clinical characteristics were analyzed 
using descriptive statistics; factors associated with treatment changes were exam-
ined using Cox proportional hazard regression models. Results: 59% of MAPD 
patients (mean age 69.6 years) remained on MET monotherapy with no changes. 
Discontinuation was the most common treatment change (33%), followed by addi-
tion (5%), and switching (2%). Of patients who discontinued treatment (median 
time to discontinuation= 90 days), 61% did not re-initiate any diabetic treatment 
during the 12 month follow-up period. Among those who added or switched to 
other antidiabetics, sulfonylureas were the most commonly-added or switched-
to drugs. Discontinuation was predicted by being female (hazard ratio [HR] 1.06, 
[1.003;1.12]95%CI), having more comorbidities (HR 1.00, [1.01;1.04]95%CI) or a diag-
nosis of depression (HR 1.18, [1.08;1.27]95%CI) in the 12 months before initiating 
MET; in MAPD aged ≥ 65 (n= 14,389), discontinuation was predicted by a higher 
baseline daily average consumption (DACON) of MET (HR 1.00, [1.0002;1.0006]95%CI).  
ConClusions: Discontinuation of MET was the most common treatment change 
in this population. Being female, having a higher baseline DACON of MET, more 
comorbidities or a diagnosis of depression were all predictors of discontinuation.
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objeCtives: Early metabolic abnormalities that precede diabetes (impaired fast-
ing glucose and impaired glucose tolerance) are associated with increased mortal-
ity. Our study aimed to assess the relationship between random glucose levels 
and development of all-cause mortality, specifically considering the differences 
between normal, high-normal glucose, pre-diabetes and diabetes. Methods: A 
retrospective cohort study using a limited dataset from the Framingham Heart 
Study was employed. Baseline-period was in 1956, each patient was followed 
24 years. Random glucose was grouped into normal, high-normal, pre-diabetes, 
and diabetes. Ages, gender, body mass index, and blood pressure were examined. 
Outcome measure was all-cause mortality. Bivariate and multivariate cox propor-
tional hazards regression models controlling for demographics and risk factors 
were performed to compare the risk of death between different random glucose 
levels. Results: The study cohort consisted of 3,270 survey patients with a mean 
age 50(±8.68), of which 1,825(55.8%) were female. During the follow-up period, 1,178 
patients deceased. The average follow-up time was 20 years; while average sur-
vival time for patients who deceased was 14 years. Compared to normal random 
glucose, high-normal (Hazard Ratio[HR]:1.486; Confidence Interval[CI]:1.24 –1.77), 
pre-diabetes (HR:3.328; CI:2.237–4.951) and diabetes (HR:5.314; CI:3.754–7.523) were 
significantly associated with increased risk of all-cause death in the bivariate Cox 
regression model. In adjusted model, high-normal glucose level (HR:1.216; CI:1.019–
1.45), pre-diabetes(HR:2.458; CI:1.647–3.667), and diabetes (HR:3.164; CI:2.214– 4.521) 
were significantly associated with increased risk of death compared to normal 
glucose group; age and hypertensive systolic blood pressure were associated with 
increased risk of all-cause death; while female gender was significantly associated 
with decreased risk of death. ConClusions: Random glucose alone can predict 
risk and even high-normal levels are associated with increased mortality. Our find-
ings are of value especially when considering cost-effective strategies in screening 
underserved populations throughout the globe, where medical resources are scarce 
and fasting glucose levels are difficult to obtain.
PDB122
the imPaCt of treatment Patterns anD the risk of severe 
hyPoglyCaemia events in tyPe 1&2 DiaBetes mellitus in five Central 
euroPean Countries
Jakubczyk M.1, Paweska J.2, Niewada M.3, Rdzanek E.2, Dolezal T.4, Nagy B.5, Saric T.6,  
Czech M.7
1Institute of Econometrics, Warsaw School of Economics, Warsaw, Poland, 2HealthQuest spolka 
z ograniczona odpowiedzialnoscia Sp. K., Warsaw, Poland, 3Department of Experimental and 
Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland, 4Institute of Health 
Economics and Technology Assessment, Prague, Czech Republic, 5Healthware Ltd, Budapest, 
Hungary, 6Promeritus savjetovanje, Zagreb, Croatia, 7Novo Nordisk Pharma Sp z.o.o., Warsaw, 
Poland
objeCtives: Severe (requiring another person’s assistance) hypoglycaemic events 
(SHEs) matter from clinical and economic perspective. Various risk factors are men-
tioned in the literature (drugs used, patients’ adherence, diet, exercise). We aimed 
to compare diabetes mellitus (DM) treatment patterns in Croatia, Czech Republic, 
Hungary, Poland and Slovenia with respect to the resulting risk of SHE. Methods: 
We performed a systematic review to assess the drug related annual SHE rates for 
various treatments (shown in past ISPOR meetings) defined depending on using oral 
antidiabetic medications, sulfonylureas, insulins–split into basal-bolus/biphasic, 
and analogues/human. Epidemiological data were based on national registries, pre-
scription databases, published studies, questionnaire surveys. Market shares were 
based on IMS data (Croatia, Czech Republic, Poland), National Health Insurance Fund 
(Hungary), prescription database (Slovenia). Results: Using SHE rates estimates 
for individual treatment schemes and epidemiological and market data we arrived 
at the following estimates of the annual total number of SHEs: Croatia – 16,975, 
Czech Republic – 80,884, Hungary – 62,282, Poland – 217,711, and Slovenia – 9,291. 
When expressed per one DM patient we got annually: 0.078, 0.117, 0.143, 0.120, 0.096, 
